R&D
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global pharmaceutical R&D trends, drug discovery pipelines, and clinical trial advancements. Drive your pharma strategy.
Showing 1–12 of 117 articles
Quick answer
NovaPharmaNews R&D hub for FDA covers 117 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Adial Pharmaceuticals Completes Azora Merger, Expands Ulcerative Colitis Pipeline
FDA · 3 min
Michael RiveraBiotech’s coming of age: AI, capital efficiency and China reshape the field
4 min
Dr. Sarah MitchellEdgewise Therapeutics’ EDG-7500 clears key Phase 2 test
hypertrophic cardiomyopathy · 5 min
Dr. Sarah MitchellCeliac disease therapies enter a new era of innovation
Celiac disease · 4 min
Dr. Sarah MitchellNeumora navacaprant fails Phase 3 as EnGene cuts 50% of staff
depression · 5 min
Dr. Sarah MitchellGlobal hematology trials keep research patient-centered and regionally relevant
EMA · hematological malignancy · 4 min
Dr. Sarah MitchellHillhurst Bio doses first subject in Phase 2a HBI-002 Parkinson's trial
FDA · Parkinson's disease · 5 min
Dr. Sarah MitchellPlanning a successful pivot from lab to clinic: a practical career map
4 min
Dr. Sarah MitchellHFMA conference: Affordability was the focus, but fixes remained unclear
4 min
Dr. Sarah MitchellFDA Clears First OTC CGM for Children: Dexcom Expands Stelo
FDA · diabetes · 4 min
Dr. Sarah MitchellFDA authorizes generic nitenpyram for New World screwworm in pets
FDA · New World screwworm · 5 min
Dr. Sarah MitchellHHS responds coolly to alcohol risk paper amid cancer-warning debate
HHS · liver cancer · 4 min
Dr. Sarah MitchellFrequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.
Explore intelligence